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• TTCs’ interest in smokeless tobacco dates back to 1971 when BAT first started  scoping 
opportunities in Western Europe in partnership with US Tobacco Company. 
• Prompted by fear of declining cigarette sales, BAT considered smokeless tobacco to be a 
cigarette alternative (not replacement!) for: 
• Smokers that considered quitting due to health concerns; 
• Smokers in smokefree environments; and
• New generation of ‘better educated’ not interested in smoking
• Young people were a key target.
• Example: extract of  a 1981 BAT Tobacco Executive Committee briefing, dated 21 September 
1981, available at http://legacy.library.ucsf.edu/tid/hxf18a99):
• Despite recognising the lower health risks of smokeless tobacco, TTCs did not invest until 
2002 when a number of risks and opportunities coincided: Europe’s cigarette volumes started 
declining, smokefree legislation was an emerging threat, and public health first started 
showing interest in harm reduction  triggered by the (US) Institute of Medicine ‘Clearing the 
Smoke’ report (2001) which investigated the feasibility of tobacco harm reduction.
• TTCs adopted the term ‘harm reduction’ from the IOM, and thereafter increasingly used the 
term in its corporate messaging. For example, BAT’s use of the term “harm reduction” in its 
social reports increased from 2 in 2001/2 to 247 in 2010. 
• Despite this messaging, we found no evidence that snus was central to TTCs’ business 
strategies. Instead, documents and interviews suggest harm reduction offered TTCs two main 
benefits: reputation enhancement and an opportunity to (re) establish dialogue with, and 
access to, policy makers, scientists, and public health groups.
• Nevertheless, all TTCs now have a snus interest, leaving no major European snus 
manufacturer independent of cigarette interests, thereby reducing competition between snus 
and cigarettes. 
• While far less evidence is available on nicotine-containing products and e-cigarettes, the 
TTCs recent investment in these products and statements that “new ‘would be smokers’ 
begin with and stay with low risk product categories” (BAT Investor presentation 2011), 
raise concerns that the TTCs may also be attempting to control this market. 
Analysis of internal tobacco industry documents (http://legacy.library.ucsf.edu/)
• 455 relevant documents (covering period 1971-2009) analysed 
• Focus on British American Tobacco (BAT) and Philip Morris International (PMI)
Analysis of secondary literature accessed via the British Library and internet: 
• Company reports (BAT n=14, PMI n=9), investor presentations (BAT n=42, PMI n=47), 
Sustainability reports (BAT n=11) and corporate websites (bat.com, pmi.com)
• Reports on tobacco industry investments via Nexis UK (media) and industry journals
• Internet Archive Wayback Machine:( (search on  bat.com  1996-2012)
• Euromonitor reports on developments and trends in the European tobacco market
Stakeholder interviews
• 3 Swedish public health experts
• 4 tobacco industry  representatives 
“I believe that tobacco harm reduction has the potential to be one of the biggest 
public health opportunities of this generation” 
(David O’Reilly, British American Tobacco Scientific Director, bat-science.com  Nov. 2013)
• Tobacco harm reduction approach: lives can be saved if smokers switch from cigarettes to 
using nicotine in a less hazardous form. 
• Public health divided on this issue: should a harm reduction approach involve reduced risk 
products such as  smokeless tobacco (in particular Swedish snus ) or e-cigarettes?
• Snus sales banned in Europe, except for in Sweden, but legislation currently under review. 
• Transnational tobacco companies (TTCs) have argued that health gains can be gained if 
governments allow potentially reduced risk products like snus on the market. 
• There are concerns that TTCs might market reduced risk products in a way that sustains and 
promotes, rather than reduces, smoking.
Objective: To explore the tobacco industry’s rationale for, and approaches to reduced risk 
products and promoting harm reduction. Focus on Europe and smokeless tobacco. 
1. TTCs’ rhetoric on harm reduction is inconsistent with historical and recent TTC documents 
and action, both of which suggest that TTCs may have little intention of promoting snus use 
in a way envisioned by public health, as this would eat into their existing cigarette profits. 
2. TTCs’ snus investments have been defensive instead, turning snus from a threat (a product 
that might have competed with cigarettes) into a major opportunity: one that enables TTCs 
to claim a joint agenda with public health and to rehabilitate their reputation.
3. By investing in snus, and recently nicotine, TTCs are eliminating competition between 
cigarettes and lower-risk products, thus helping maintain the current market balance in 
favour of (highly profitable) cigarettes, while ensuring TTCs’ long-term future should 
cigarette sales decline further and profit margins be eroded.
• Legalising snus sales in Europe may have considerably less benefit than envisaged and 
could have a number of harmful consequences.
• TTC investments in reduced risk products are likely to reduce the ability of reduced risk 
products to contribute to harm reduction and should be carefully monitored. 
• TTCs should be prevented from using their investments in reduced risk products to 
undermine Article 5.3. of the Framework Convention on Tobacco Control which aims to 
protect public health policy from commercial and other vested interests of the tobacco 
industry.
The tobacco industry’s harm reduction discourse should be seen as opportunistic 
tactical adaptation to policy change rather than a genuine commitment to harm 
reduction.  Care should be taken that this does not undermine gains hitherto 
secured in efforts to reduce the ability of the tobacco industry to inappropriately 
influence public health policy, or the ability of reduced risk products to reduce harm 
from tobacco.
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